To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults With Moderate-to-severe Atopic Dermatitis
A Phase IIa, Double-Blind, Randomised, Placebo-controlled, Exploratory Study to Evaluate the Safety, Biological Activity and Pharmacokinetics of GBR 830 in Adults With Moderate-to-Severe Atopic Dermatitis
Sponsor: Glenmark Pharmaceuticals S.A.
Listed as NCT02683928, this PHASE2 trial focuses on Atopic Dermatitis and remains completed. Sponsored by Glenmark Pharmaceuticals S.A., it has been updated 13 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
▶ Show 8 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
-
Jun 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Jul 2018 — Jun 2020 [monthly]
Completed PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Aug 2017 — Sep 2017 [monthly]
Recruiting PHASE2
-
Feb 2017 — Aug 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Mar 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Glenmark Pharmaceuticals S.A.
- Ichnos Sciences SA
For direct contact, visit the study record on ClinicalTrials.gov .